Simple math illustrates the challenge facing U.S. taxpayers, consumers and insurers following the launch late last year of two expensive new drugs to treat hepatitis C. If all 3 million people ...

Glecaprevir/pibrentasvir cleared infection in nearly all patients in a global phase IIIb s ...

(Reuters) - Achillion Pharmaceuticals Inc said the U.S. Food and Drug Administration decided not to lift a clinical hold it had placed on the firm's hepatitis C drug, sovaprevir, leaving an uncertain ...

Ten years ago, safe and effective treatments for hepatitis C became available. These pills are easy-to-take oral antivirals with few side effects. They cure 95% of patients who take them. The ...

Louisiana is communicating with CMS to explore a subscription-based payment model for hepatitis C treatments, according to a proposal the Louisiana Department of Health released this week. The health ...

WASHINGTON (AP) — An innovative hepatitis C drug that was only recently hailed as a breakthrough treatment is facing skepticism from some health care providers, as they consider whether it is worth ...

(AP) The Food and Drug Administration has issued a positive review for a highly anticipated hepatitis C drug from Gilead Sciences, saying the pill cures more patients in less time than currently ...

Hepatitis C is an infection of the liver caused by the hepatitis C virus (HCV). Experts estimate that about 2.4 million people in the United States are living with hepatitis C—but that figure could be ...

New Haven drug developer Achillion Pharmaceuticals Inc. has launched its first human trial of one of its treatment for chronic hepatitis C. The company says the double-blind Phase 1 study of its ...

NEW YORK (Reuters) - A hepatitis C treatment being developed by Vertex Pharmaceuticals Inc led to a 75 percent cure rate in a pivotal trial of previously untreated patients, the company said on ...

The American Hospital Association and several hospital systems are suing the Trump Administration over an upcoming 340B pilot ...